1. New Drugs at FDA: CDER’s new molecular entities and new therapeutic biological products. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ . Accessed 06 May 2016.
2. Shargel L, Wu-Pong S, Yu A. Chapter 17. Modified-release drug products. In: Shargel LW-P, S; Yu AC, eds. Applied Biopharmaceutics & Pharmacokinetics. New York, NY: McGraw-Hill; 2012. http://accesspharmacy.mhmedical.com/content.aspx?bookid=513&Sectionid=41488035. Accessed 03 May 2016
3. Office of Pharmaceutical Quality, FDA Pharmaceutical Quality Oversight, One Quality Voice. 2015. http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM442666.pdf . Accessed 06 May 2016.
4. U.S. Food and Drug Administration. Guidance for industry Q9 quality risk management. 2006.
5. U.S. Food and Drug Administration. Guidance for industry Q8(R2) pharmaceutical development. 2009.